Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | SQLE | Q14534 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838745 | 0.97 | NR1I2 (0.71) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL39207 | 0.86 | NR1I2 (0.62) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL116111 | 0.86 | NR1I2 (0.62) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2838750 | 0.86 | NR1I2 (0.62) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2832254 | 0.85 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2836986 | 0.85 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL323577 | 0.85 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL30578160 | 0.85 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2834897 | 0.85 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2837840 | 0.85 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | EDNRB, EDNRA, ADRB1 | NR1I2 967/4885LMNA 862/4885PGR 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.